Shenzhen Hepalink Pharmaceutical Co Ltd (002399) — Financial Flexibility Index
Shenzhen Hepalink Pharmaceutical Co Ltd (002399) has a Financial Flexibility Index of 0.09x as of September 2025. Free cash flow of CN¥413.04 Million (operating CF CN¥399.43 Million minus capex CN¥13.60 Million) represents 0% of total liabilities (CN¥4.70 Billion). Check asset allocation strategy of Shenzhen Hepalink Pharmaceutical Co Ltd to assess the company's strategic physical and investment asset allocation.
Financial Flexibility Index
Free Cash Flow
Total Liabilities
Capital Expenditures
Shenzhen Hepalink Pharmaceutical Co Ltd Financial Flexibility Index (2006–2025)
Historical Financial Flexibility Index trend for Shenzhen Hepalink Pharmaceutical Co Ltd across 20 annual periods. See 002399 working capital efficiency to evaluate short-term liquidity relative to the company's equity base.
Annual Financial Flexibility Index for Shenzhen Hepalink Pharmaceutical Co Ltd (2006–2025)
Year-by-year free cash flow to debt coverage for Shenzhen Hepalink Pharmaceutical Co Ltd. For the full company profile including market capitalisation, see 002399 market cap overview.
| Year | Flexibility Index | Free Cash Flow (CNY) | Operating CF | Total Liabilities | YoY Change |
|---|---|---|---|---|---|
| 2025 | 0.40x | CN¥1.83 Billion | CN¥1.71 Billion | CN¥4.55 Billion | ▼ -13.6% |
| 2024 | 0.47x | CN¥2.40 Billion | CN¥2.19 Billion | CN¥5.14 Billion | ▲ +299.0% |
| 2023 | 0.12x | CN¥843.09 Million | CN¥398.22 Million | CN¥7.22 Billion | ▲ +283.9% |
| 2022 | -0.06x | CN¥-534.19 Million | CN¥-756.61 Million | CN¥8.41 Billion | ▼ -357.4% |
| 2021 | 0.02x | CN¥187.23 Million | CN¥-6.63 Million | CN¥7.58 Billion | ▼ -27.5% |
| 2020 | 0.03x | CN¥249.77 Million | CN¥37.28 Million | CN¥7.34 Billion | ▲ +96.7% |
| 2019 | 0.02x | CN¥134.47 Million | CN¥-227.60 Million | CN¥7.77 Billion | ▼ -89.3% |
| 2018 | 0.16x | CN¥1.20 Billion | CN¥667.87 Million | CN¥7.41 Billion | ▲ +428.5% |
| 2017 | 0.03x | CN¥169.01 Million | CN¥-407.12 Million | CN¥5.50 Billion | ▼ -79.0% |
| 2016 | 0.15x | CN¥705.61 Million | CN¥346.07 Million | CN¥4.83 Billion | ▼ -53.5% |
| 2015 | 0.31x | CN¥1.06 Billion | CN¥893.71 Million | CN¥3.38 Billion | ▼ -54.0% |
| 2014 | 0.68x | CN¥1.08 Billion | CN¥912.80 Million | CN¥1.58 Billion | ▼ -80.5% |
| 2013 | 3.51x | CN¥714.94 Million | CN¥420.97 Million | CN¥203.80 Million | ▲ +5.8% |
| 2012 | 3.32x | CN¥711.44 Million | CN¥473.89 Million | CN¥214.53 Million | ▼ -87.1% |
| 2011 | 25.67x | CN¥1.54 Billion | CN¥1.41 Billion | CN¥59.98 Million | ▲ +579.3% |
| 2010 | 3.78x | CN¥390.80 Million | CN¥354.86 Million | CN¥103.44 Million | ▲ +181.8% |
| 2009 | 1.34x | CN¥410.72 Million | CN¥355.81 Million | CN¥306.33 Million | ▲ +613.5% |
| 2008 | 0.19x | CN¥50.94 Million | CN¥40.13 Million | CN¥271.09 Million | ▼ -18.9% |
| 2007 | 0.23x | CN¥25.80 Million | CN¥13.85 Million | CN¥111.28 Million | ▼ -27.5% |
| 2006 | 0.32x | CN¥82.36 Million | CN¥71.66 Million | CN¥257.68 Million | — |